PE20120543A1 - ANTI-TAU ANTI-BODY PS422 - Google Patents
ANTI-TAU ANTI-BODY PS422Info
- Publication number
- PE20120543A1 PE20120543A1 PE2011002053A PE2011002053A PE20120543A1 PE 20120543 A1 PE20120543 A1 PE 20120543A1 PE 2011002053 A PE2011002053 A PE 2011002053A PE 2011002053 A PE2011002053 A PE 2011002053A PE 20120543 A1 PE20120543 A1 PE 20120543A1
- Authority
- PE
- Peru
- Prior art keywords
- tau
- phosphorilated
- seq
- antibody
- disease
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 201000011240 Frontotemporal dementia Diseases 0.000 abstract 1
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 abstract 1
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 abstract 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
Abstract
REFERIDA A UN ANTICUERPO QUE SE UNE A LA TAU FOSFORILADA EN LA SERINA 422 (TAU PS422) QUE SE UNE ESPECIFICAMENTE AL FRAGMENTO TAU FOSFORILADO DE LA SEQ ID NO:9 Y A LA TAU PS422 PERO QUE NO SE UNE A LA TAU NI AL FRAGMENTO MCAK FOSFORILADO DE LA SEQ ID NO:17, DONDE DICHO ANTICUERPO ES DE LOS SUBTIPOS IgG1 O IgG4. TAMBIEN ESTA REFERIDA A UN ACIDO NUCLEICO Y A UNA COMPOSICION FARMACEUTICA. DICHOS ANTICUERPOS SON UTILES EN EL TRATAMIENTO DE TAUOPATIAS TALES COMO LA ENFERMEDAD DE ALZHEIMER, DEMENCIA PUGILISTICA, LA ENFERMEDAD DE PICK, ENTRE OTRASREFERRING TO AN ANTIBODY THAT IS JOINED TO THE PHOSPHORILATED TAU IN SERINE 422 (TAU PS422) THAT IS SPECIFICALLY JOINED TO THE PHOSPHORILATED TAU FRAGMENT OF SEQ ID NO: 9 AND TO THE TAU PS422 BUT NOT JOINING THE TAU OR THE MCAK FRAGMENT PHOSPHORYLATE OF SEQ ID NO: 17, WHERE SAID ANTIBODY IS OF THE IgG1 OR IgG4 SUBTYPES. IT IS ALSO REFERRED TO A NUCLEIC ACID AND TO A PHARMACEUTICAL COMPOSITION. SUCH ANTIBODIES ARE USEFUL IN THE TREATMENT OF TAUOPATIAS SUCH AS ALZHEIMER'S DISEASE, PUGILISTIC DEMENTIA, PICK'S DISEASE, AMONG OTHERS
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09007656 | 2009-06-10 | ||
| EP09008487 | 2009-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20120543A1 true PE20120543A1 (en) | 2012-05-23 |
Family
ID=42753372
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011002053A PE20120543A1 (en) | 2009-06-10 | 2010-06-08 | ANTI-TAU ANTI-BODY PS422 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8609097B2 (en) |
| EP (1) | EP2440578B1 (en) |
| JP (2) | JP2012529275A (en) |
| KR (1) | KR101429367B1 (en) |
| CN (1) | CN102459333B (en) |
| AR (1) | AR077016A1 (en) |
| AU (1) | AU2010257799B2 (en) |
| BR (1) | BRPI1012993A2 (en) |
| CA (1) | CA2762594C (en) |
| CL (1) | CL2011003122A1 (en) |
| CO (1) | CO6450613A2 (en) |
| CR (1) | CR20110606A (en) |
| EC (1) | ECSP11011514A (en) |
| IL (1) | IL216509A0 (en) |
| MA (1) | MA33339B1 (en) |
| MX (1) | MX2011012837A (en) |
| NZ (1) | NZ596187A (en) |
| PE (1) | PE20120543A1 (en) |
| RU (1) | RU2536247C2 (en) |
| SG (1) | SG176754A1 (en) |
| TW (1) | TW201103560A (en) |
| WO (1) | WO2010142423A2 (en) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007114319A1 (en) | 2006-03-31 | 2007-10-11 | Chugai Seiyaku Kabushiki Kaisha | Method for control of blood kinetics of antibody |
| EP3127921A1 (en) | 2007-09-26 | 2017-02-08 | Chugai Seiyaku Kabushiki Kaisha | Method of modifying isoelectric point of antibody via amino acid substition in cdr |
| EP2708559B1 (en) | 2008-04-11 | 2018-03-28 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| DK3345903T3 (en) | 2009-06-10 | 2019-11-11 | Chugai Pharmaceutical Co Ltd | Tetracyclic compounds |
| CN103052386B (en) | 2010-08-20 | 2016-03-02 | 中外制药株式会社 | Compositions containing tetracyclic compound |
| MX345092B (en) | 2010-10-11 | 2017-01-17 | Univ Zuerich | Human anti-tau antibodies. |
| TWI654204B (en) | 2010-11-30 | 2019-03-21 | 中外製藥股份有限公司 | Antibody with calcium-dependent antigen binding ability |
| GB201112056D0 (en) * | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
| MX347505B (en) | 2011-09-19 | 2017-04-28 | Axon Neuroscience Se | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease. |
| HRP20191342T1 (en) | 2011-12-20 | 2019-11-01 | Janssen Biotech Inc | Anti-phf-tau antibodies and their uses |
| CN109810188A (en) | 2011-12-21 | 2019-05-28 | 弗·哈夫曼-拉罗切有限公司 | For cloning and expressing the fast method of cognate antibodies variable gene segment |
| NZ630536A (en) | 2012-05-31 | 2017-03-31 | Teijin Pharma Ltd | Therapeutic agent or prophylactic agent for dementia |
| WO2014028777A2 (en) | 2012-08-16 | 2014-02-20 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6774164B2 (en) | 2012-08-24 | 2020-10-21 | 中外製薬株式会社 | Mouse FcγRII specific Fc antibody |
| RU2729831C2 (en) | 2012-08-24 | 2020-08-12 | Чугаи Сейяку Кабусики Кайся | Versions of fcγriib-specific fc-region |
| SG11201502211QA (en) | 2012-09-25 | 2015-05-28 | Chugai Pharmaceutical Co Ltd | Ret inhibitor |
| WO2014096321A1 (en) * | 2012-12-21 | 2014-06-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies specific to tau phosphorylated at serine 422 and uses for the treatment and diagnosis of tauopathies |
| CN111205368B (en) * | 2012-12-21 | 2023-05-09 | 比奥根Ma公司 | Human anti-TAU antibodies |
| US8980270B2 (en) | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| KR20210130260A (en) | 2013-04-02 | 2021-10-29 | 추가이 세이야쿠 가부시키가이샤 | Fc region variant |
| RS60031B1 (en) | 2013-12-20 | 2020-04-30 | Hoffmann La Roche | Humanized anti-tau(ps422) antibodies and methods of use |
| EP2899208A1 (en) | 2014-01-28 | 2015-07-29 | F.Hoffmann-La Roche Ag | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof |
| JP2017512751A (en) | 2014-02-14 | 2017-05-25 | アイピエリアン，インコーポレイティド | Tau peptides, anti-tau antibodies, and methods for their use |
| TWI831128B (en) | 2014-04-25 | 2024-02-01 | 日商中外製藥股份有限公司 | Formulation comprising tetracyclic compounds in high dose |
| KR20220042486A (en) | 2014-04-25 | 2022-04-05 | 추가이 세이야쿠 가부시키가이샤 | Novel crystal of tetracyclic compound |
| AR100978A1 (en) * | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | ANTI-Tau HUMANIZED ANTIBODY BRAIN LAUNCHERS (pS422) AND USES OF THE SAME |
| TWI734975B (en) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | Humanized anti-tau antibodies |
| TWI718102B (en) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | Amorphous body of tetracyclic compound |
| US9732148B2 (en) * | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| US10160799B2 (en) * | 2014-11-19 | 2018-12-25 | Axon Neuroscience Se | Humanized tau antibodies in a alzheimer's disease |
| CA2963760A1 (en) | 2014-12-19 | 2016-06-23 | Yoshinao Ruike | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
| JP6741596B2 (en) | 2015-01-16 | 2020-08-19 | 中外製薬株式会社 | Concomitant medication |
| MX2017008978A (en) | 2015-02-05 | 2017-10-25 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof. |
| TWI669314B (en) | 2015-02-26 | 2019-08-21 | 美國禮來大藥廠 | Antibodies to tau and uses thereof |
| JP6917899B2 (en) * | 2015-04-16 | 2021-08-11 | ハー・ルンドベック・アクチエゼルスカベット | Anti-PACAP antibodies and their use |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| EP3313877B1 (en) * | 2015-06-24 | 2020-06-03 | H. Hoffnabb-La Roche Ag | Humanized anti-tau(ps422) antibodies and methods of use |
| US10344081B2 (en) | 2015-07-06 | 2019-07-09 | Ucb Biopharma Sprl | Tau-binding antibodies |
| KR102770650B1 (en) * | 2015-07-06 | 2025-02-19 | 유씨비 바이오파마 에스알엘 | Tau binding antibody |
| JO3711B1 (en) | 2015-07-13 | 2021-01-31 | H Lundbeck As | Antibodies specific for hyperphosphorylated tau and methods of use thereof |
| FI3334761T3 (en) * | 2015-08-13 | 2023-08-14 | Univ New York | Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy |
| WO2017110981A1 (en) | 2015-12-25 | 2017-06-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-myostatin antibodies and methods of use |
| CN109311977B (en) | 2016-04-15 | 2022-06-14 | H.伦德贝克公司 | Humanized anti-PACAP antibodies and uses thereof |
| RU2760875C1 (en) | 2016-07-12 | 2021-12-01 | Х. Лундбекк А/С | Antibodies specific to hyperphosphorylated tau-protein and their application methods |
| TWI831965B (en) | 2016-08-05 | 2024-02-11 | 日商中外製藥股份有限公司 | Compositions for the treatment or prevention of IL-8 related diseases |
| JP6949102B2 (en) | 2016-08-09 | 2021-10-13 | イーライ リリー アンド カンパニー | Combination therapy |
| TW202328181A (en) | 2016-12-07 | 2023-07-16 | 美商建南德克公司 | Anti-tau antibodies and methods of use |
| CA3045294A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| GB201700487D0 (en) | 2017-01-11 | 2017-02-22 | Hermon-Taylor John | Diagnostic |
| AU2018221049A1 (en) | 2017-02-17 | 2019-09-19 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (en) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | Humanized antibody for treating or preventing dementia and production method therefor and therapeutic agent or prophylactic agent for dementia using same |
| JOP20180021A1 (en) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | Anti-phf-tau antibodies and uses thereof |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| EA202091756A1 (en) | 2018-02-01 | 2020-10-28 | Янссен Вэксинс Энд Превеншн Б.В. | BINDING MOLECULES SPECIFICALLY BINDING TO TAU PROTEIN |
| US12234280B2 (en) | 2018-03-05 | 2025-02-25 | Janssen Pharmaceutica Nv | Anti-PHF-tau antibodies and uses thereof |
| CN112567033A (en) | 2018-07-03 | 2021-03-26 | 豪夫迈·罗氏有限公司 | Oligonucleotides for modulating Tau expression |
| GB201811382D0 (en) | 2018-07-11 | 2018-08-29 | Taylor John Hermon | Vaccine |
| CA3107788A1 (en) | 2018-07-31 | 2020-02-06 | Eli Lilly And Company | Combination of anti-tau antibody and oga inhibitor for treatment of diseases characterized by aberrant tau aggregation |
| HRP20250284T1 (en) | 2018-09-04 | 2025-04-25 | Chugai Seiyaku Kabushiki Kaisha | PROCESS FOR OBTAINING A TETRACYCLIC COMPOUND |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| US11702467B2 (en) | 2020-06-25 | 2023-07-18 | Merck Sharp & Dohme Llc | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN120019071A (en) | 2022-09-15 | 2025-05-16 | 沃雅戈治疗公司 | TAU-binding compounds |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| EP0618968B1 (en) | 1991-12-06 | 1999-10-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Tools for the diagnosis and treatment of alzheimer's disease |
| US20020086009A1 (en) | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| AU5508798A (en) | 1996-11-19 | 1998-06-10 | Trustees Of The University Of Pennsylvania, The | Diagnostic and therapeutic reagents for alzheimer's disease |
| IT1312107B1 (en) * | 1999-05-14 | 2002-04-04 | Umberto Cornelli | GLYCOSAMINOGLICANS HAVING AVERAGE MOLECULAR WEIGHT OF 2400 D ACTS TREATMENT OF SENILE DEEMENT |
| AT500379B8 (en) | 2001-02-02 | 2009-08-15 | Axon Neuroscience | TAU PROTEINS |
| US8012936B2 (en) * | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP1876185A1 (en) | 2006-07-04 | 2008-01-09 | F. Hoffmann-La Roche Ag | An antibody which recognizes phosphorylated polypeptides |
-
2010
- 2010-06-03 US US12/792,810 patent/US8609097B2/en not_active Expired - Fee Related
- 2010-06-07 TW TW099118463A patent/TW201103560A/en unknown
- 2010-06-08 PE PE2011002053A patent/PE20120543A1/en not_active Application Discontinuation
- 2010-06-08 MA MA34419A patent/MA33339B1/en unknown
- 2010-06-08 KR KR1020127000595A patent/KR101429367B1/en not_active Expired - Fee Related
- 2010-06-08 AR ARP100102006A patent/AR077016A1/en not_active Application Discontinuation
- 2010-06-08 SG SG2011091139A patent/SG176754A1/en unknown
- 2010-06-08 WO PCT/EP2010/003437 patent/WO2010142423A2/en not_active Ceased
- 2010-06-08 EP EP10722962.7A patent/EP2440578B1/en active Active
- 2010-06-08 CA CA2762594A patent/CA2762594C/en not_active Expired - Fee Related
- 2010-06-08 JP JP2012514380A patent/JP2012529275A/en active Pending
- 2010-06-08 AU AU2010257799A patent/AU2010257799B2/en not_active Ceased
- 2010-06-08 BR BRPI1012993A patent/BRPI1012993A2/en not_active Application Discontinuation
- 2010-06-08 CN CN201080025548.1A patent/CN102459333B/en not_active Expired - Fee Related
- 2010-06-08 NZ NZ596187A patent/NZ596187A/en not_active IP Right Cessation
- 2010-06-08 MX MX2011012837A patent/MX2011012837A/en active IP Right Grant
- 2010-06-08 RU RU2011152816/10A patent/RU2536247C2/en active
-
2011
- 2011-10-31 CO CO11147439A patent/CO6450613A2/en not_active Application Discontinuation
- 2011-11-16 CR CR20110606A patent/CR20110606A/en unknown
- 2011-11-21 IL IL216509A patent/IL216509A0/en unknown
- 2011-12-09 EC EC2011011514A patent/ECSP11011514A/en unknown
- 2011-12-09 CL CL2011003122A patent/CL2011003122A1/en unknown
-
2013
- 2013-06-06 US US13/911,991 patent/US9290567B2/en not_active Expired - Fee Related
-
2016
- 2016-09-16 JP JP2016181500A patent/JP6513617B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20120543A1 (en) | ANTI-TAU ANTI-BODY PS422 | |
| PE20090726A1 (en) | APOPTOTIC ANTI-IGE ANTIBODIES | |
| NZ584893A (en) | PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF | |
| PE20121360A1 (en) | NEUTRALIZING ANTIBODIES AGAINST THE PROLACTIN RECEPTOR | |
| BR112014012275A2 (en) | protein purification using bis-tris buffer | |
| NZ597692A (en) | Anti-IGF antibodies | |
| CY1120413T1 (en) | SPECIALLY HUMANIZED ANTIBODIES IN THE PROTEINOLOGICAL FORM OF BETA-AMYLOID Peptide | |
| PE20141162A1 (en) | ANTI-IL-23 ANTIBODIES | |
| GT200600186A (en) | UNION AGENTS | |
| MX359680B (en) | Peptide vaccines for cancers expressing tumor-associated antigens. | |
| EA201290370A1 (en) | ANTIBODIES AGAINST FLT3 AND METHODS OF THEIR APPLICATION | |
| EA200801571A1 (en) | COMPOSITIONS CONTAINING CTL4-IG MOLECULES AND METHODS FOR THEIR RECEPTION | |
| BR112012011740A2 (en) | polypeptide, a composition comprising said polypeptide, protein complex, nucleotide sequence, cell expression vector, and methods for preparing the protein complex, for preparing a fviii, and for enhancing a plasma pharmacokinetic property of a fviii | |
| ECSP077282A (en) | PROCESS FOR THE CONCENTRATION OF ANTIBODIES AND THERAPEUTIC PRODUCTS OF THE SAME | |
| UA111818C2 (en) | ANTIBODY AGAINST CSF-1R | |
| PE20120340A1 (en) | ANTI-TUMOR COMBINATIONS CONTAINING ANTIBODIES THAT SPECIFICALLY RECOGNIZE CD38 AND MELFALAN | |
| EA201490677A1 (en) | BONDING ANTIGEN CD27L PROTEINS | |
| MA33208B1 (en) | ANTI-FGFR3 ANTIBODIES AND METHODS OF USE THEREOF | |
| CR9253A (en) | HER ANTIBODY DOSAGE SETTING | |
| CR10555A (en) | VACCINES FOR MALARIA | |
| CL2008001887A1 (en) | PROTEINS OF UNION TO ANTIGEN THAT JOIN THE RECEPTOR ACTIVATED BY PROTEASES 2 (PAR-2); NUCLEIC ACID THAT CODES THEM; VECTOR AND GUEST CELL; METHOD OF PRODUCTION; AND COMPOSITION THAT UNDERSTANDS THEM. | |
| DE602006006200D1 (en) | ANTIBODY AGAINST 25-HYDROXYVITAMINE D | |
| MA34907B1 (en) | ANTIBODY MOLECULES BINDING TO IL-17A AND IL-17F | |
| MA33537B1 (en) | Antibodies against human cdcp1 | |
| PH12014502669A1 (en) | Therapeutic agent or prophylactic agent for dementia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |